January 3, 2025 06:33 AM ESTUpdated 08:35 AM
R&D

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Elizabeth Cairns

Senior biopharma journalist

With the dis­ap­point­ment of No­vo Nordisk’s in­ject­ed Ca­griSe­ma in obe­si­ty at the end of 2024,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bris­tol My­ers, Ky­owa Kirin dis­close lay­offs

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

A service from the Financial Times